Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed Feb 27, 2024 · 10-K · 58 days after period end · 0000950170-24-021074
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $871.00K | $295.00K | $2.59M | $4.23M |
| Net Income | -$24.76M | -$24.78M | -$25.93M | -$17.72M |
| EPS Diluted | — | -$0.41 | -$0.64 | — |
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 27, 2024 · 58 d after period end
